Evidence map›Paper›PMID 35600172›Full record

ArticleAnnals of medicine and surgery (2012)2022

Resistant hypertension and PRES syndrome induced by carbamazepine in a patient with SLE: A case report and literature review.

Mohammad Alsultan, Kassem Basha

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mohammad AlsultanDepartment of Nephrology, Al Assad and Al Mouwasat University Hospitals, Damascus University- Faculty of Medicine, Damascus, Syria.
Kassem BashaNephrology Department, Al Mouwasat University Hospitals, Damascus University- Faculty of Medicine, Damascus, Syria.
Al Assad University Hospital · SYDamascus University · SY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Several conditions of resistant hypertension (RHTN) have been suggested and are often associated in the same patient. Approximately 75% of patients with posterior reversible encephalopathy syndrome (PRES) have moderate to severe HTN at presentation. Case presentation: A 26- year old SLE-patient presented with seizures followed by confusion and cortical blindness, in the context of emergent HTN and MRI revealed PRES syndrome. However, antihypertensive drugs were increased to maximum doses with two HD sessions, the patient still had high measures of BP. The dilemma was to find the underlying cause of long-term RHTN in this patient, where several etiologies were implicated. We review the status in more specific details and draw a timeline, which showed constant exposer to carbamazepine from the beginning of HTN. Thereafter, converting the patient to levetiracetam resulted in resolving the RHTN. Discussion/conclusion: We discuss this case with a literature review over the past ten years, which shows only three patients with a neurologic deficit in the context of severe HTN induced by carbamazepine. In the end, determining the secondary etiology of RHTN, in this patient, is considered a diagnosis of challenge due to the coincidence with SLE and the rarity of this side effect of carbamazepine. This is considered a valuable message to always exclude all secondary causes, especially drugs effects, in ESRD-patients with multiple comorbidities.

Indexed as

CarbamazepineESRDPosterior reversible encephalopathy syndromeResistant hypertensionSLE

Identifiers

PMID35600172
PMCPMC9117529
OpenAlexW4280595786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.